ReviewTherapeutic advances in endocrinology and metabolism2019
Immunotherapy-induced endocrinopathies: assessment, management and monitoring.
Review in Therapeutic advances in endocrinology and metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review.Frontiers in endocrinology · 2024Pooled it
- Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.The oncologist · 2024Trial
- Immune checkpoint inhibitor-related endocrinopathies: from immune crosstalk to predictive biomarkers and precision management.Frontiers in endocrinology · 2026Review
- Endocrine immune-related adverse events in advanced lung cancer patients receiving immune checkpoint inhibitors: incidence, predictors and outcomes.Translational lung cancer research · 2025Article
- Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma.F&S reports · 2025Article
- Long-Term Outcomes and Toxicities in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immunotherapy Containing Regimens.Cancer reports (Hoboken, N.J.) · 2025Article
- Review
- Review
- Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre.Endocrinology, diabetes & metabolism · 2024Article
- Endocrine Immune-Related Adverse Events Are Independent Predictors of Survival in Patients with Lung Cancer.Cancers · 2024Article
- Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients.Cancers · 2024Article
- Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?Cancers · 2024Review
- Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review.BMC pulmonary medicine · 2024Review
- A Case of Myxedema Coma and Adrenal Insufficiency Post Pembrolizumab.Case reports in endocrinology · 2024Article
- Dose-dependent anti-hyperglycemic & anti-dyslipidemic potential of aqueous leaves extract ofSaudi journal of biological sciences · 2023Article
- Pembrolizumab-Induced Hypothyroidism: A Case Report.Cureus · 2023Article
- Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients.Cancer immunology, immunotherapy : CII · 2023Review
- Real-World Experience of Monitoring Practice of Endocrinopathies Associated with the Use of Novel Targeted Therapies among Patients with Solid Tumors.Medical sciences (Basel, Switzerland) · 2022Article
- Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature.Annals of translational medicine · 2022Article
- Anti‑PD‑1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy with checkpoint inhibitors has transformed the treatment of cancer, but frequently results in immune-mediated adverse events affecting multiple organs, amongst which endocrine adverse events are frequent. The patterns of endocrine adverse events differ between inhibitors of the CTLA-4 and PD-1/PD-L1 pathways, but most frequently involve the thyroid and pituitary with insulin deficient diabetes also emerging as an important adverse event. These frequently result in long-lasting hormone deficiency requiring replacement. This review explores the mechanism of action of checkpoint inhibitors and details the expected endocrine adverse events and typical presentations. The effect of high-dose glucocorticoids therapy to treat nonendocrine adverse events is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.